ClinicalTrials.gg

Program

apadamtase alfa

Also written as “TAK-755”, “SHP655” and “Recombinant ADAMTS13”.

Its studies are mostly in Purpura, Thrombotic Thrombocytopenic · Ischemic Stroke · Anemia, Sickle Cell, led by Takeda.

Furthest: phase 3, since Oct 5, 20177 company-led studies, 2 open or runningNext primary completion: Mar 16, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda72 open or runningphase 3since Oct 5, 2017Aug 12, 2014Mar 16, 2027phase 3 · NCT04683003

Also a collaborator on its studies: Takeda Development Center Americas.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 12, 2014First study: phase 1 study in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)First studyNCT02216084 · 16 enrolled · United States, Austria, Germany and more
  2. Oct 5, 2017Phase 3 study in Purpura, Thrombotic ThrombocytopenicNCT03393975 · 52 enrolled · United States, Austria, France and more
  3. Apr 5, 2019Phase 2 study in Purpura, Thrombotic ThrombocytopenicNCT03922308 · 28 enrolled · United States, Canada, France and more
  4. Jun 14, 2019Phase 1 study in Anemia, Sickle CellNCT03997760 · 19 enrolled · United States
  5. Dec 10, 2020Phase 3 study in Purpura, Thrombotic ThrombocytopenicNCT04683003 · 77 enrolled · United States, Austria, China and more
  6. Jan 24, 2023Phase 2 study in Purpura, Thrombotic ThrombocytopenicNCT05714969 · 29 enrolled · United States, Austria, Greece and more
  7. Jan 30, 2026Phase 2 study in Ischemic StrokeNCT07392450 · 222 planned · United States, Belgium, Brazil and more

Ahead

  1. Mar 16, 2027Primary completion: phase 3 study in Purpura, Thrombotic ThrombocytopenicNCT04683003
  2. Dec 6, 2027Primary completion: phase 2 study in Ischemic StrokeNCT07392450

TargetBeta

ADAMTS13 →read by rule
“A recombinant human form of a disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) that may be used as a replacement therapy for ADAMTS13 with indirect anti-thrombotic and anti-thrombocytopenic activities”NCIt, by rule
“A disintegrin and metalloproteinase with thrombospondin motifs 13 exogenous protein”ChEMBL 37, by rule

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07392450Ischemic Stroke · United States, Belgium, Brazil and more2RecruitingDec 6, 2027222
NCT05714969Purpura, Thrombotic Thrombocytopenic · United States, Austria, Greece and more2CompletedApr 16, 202629
NCT04683003Purpura, Thrombotic Thrombocytopenic · United States, Austria, China and more3Active, not recruitingMar 16, 202777
NCT03997760Anemia, Sickle Cell · United States1CompletedOct 26, 202219
NCT03922308Purpura, Thrombotic Thrombocytopenic · United States, Canada, France and more2CompletedAug 5, 202128
NCT03393975Purpura, Thrombotic Thrombocytopenic · United States, Austria, France and more3CompletedDec 28, 202352
NCT02216084Hereditary Thrombotic Thrombocytopenic Purpura (TTP) · United States, Austria, Germany and more1CompletedFeb 22, 201616

How it is read

Names in the registry

  • “TAK-755”, 5 entries
  • “SHP655”, 1 entry
  • “Recombinant ADAMTS13”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.